Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
about
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinasesMolecular Targeted Therapies of Aggressive Thyroid CancerSynthesis and Biological Evaluation of 3-Alkyl-1,5-Diaryl-1H-Pyrazoles as Rigid Analogues of Combretastatin A-4 with Potent Antiproliferative ActivityEnhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRIA novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.Significance of talin in cancer progression and metastasis.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080.Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistanceSupport of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancerKML001 displays vascular disrupting properties and irinotecan combined antitumor activities in a murine tumor model.Retargeting adenoviral vectors to improve gene transfer into tumorsELR510444, a novel microtubule disruptor with multiple mechanisms of actionA perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentRole of the cytoskeleton in formation and maintenance of angiogenic sproutsDynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.2-Amino-4-methyl-5-phenylethyl substituted-7-N-benzyl-pyrrolo[2,3-d]pyrimidines as novel antitumor antimitotic agents that also reverse tumor resistance.Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.The proliferation rate paradox in antimitotic chemotherapy.Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity.Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.An angiogenesis platform using a cubic artificial eggshell with patterned blood vessels on chicken chorioallantoic membrane.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.Structure-activity relationship and in vitro and in vivo evaluation of the potent cytotoxic anti-microtubule agent N-(4-methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride and its analogues as antitumor agents.Stilbene 5c, a microtubule poison with vascular disrupting properties that induces multiple modes of growth arrest and cell death.Separate calculation of DW-MRI in assessing therapeutic effect in liver tumors in ratsDevelopment of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapyMultifunctional nanoscale platforms for targeting of the cancer cell immortality spectrum.Microvascular modifications in diabetic retinopathy.Anti-angiogenic therapy: concept to clinic.Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism.Tubulin inhibitors: a patent review.The chicken chorioallantoic membrane model in biology, medicine and bioengineeringRecent advances in vascular disrupting agents in cancer therapy.CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.Halichondrin B amide acts as tubulin binding agent to exhibit anti-tumor efficacy in hematologic cancersCombretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface
P2860
Q24617675-4750BF37-FF8A-4F6A-9D03-56A7661149BAQ26774734-8D6FE3DC-6163-43C5-B096-6B3E9C22D37DQ28548059-0AF4EA06-55A8-425D-B816-308C66F5B4DDQ28729080-DBBE1FD9-B3CA-4A31-A862-30BC7E993707Q33567298-5738CB01-4A68-4D29-B929-10AA44C96AA8Q33763551-E368C5F8-CB41-4BF0-A3F7-76D4115203E9Q34122191-A822B41D-D28E-487A-97E5-DDE5036D33CCQ34323575-DE0179F3-DC54-4FF1-BC9B-D70141EE4C5DQ34336551-A8D8F0F0-9E90-4020-8552-EDE795848CCCQ34491366-E69D3EC2-901D-4B3F-AD13-24098A21B6C9Q34538659-9228038E-8F8B-4963-8C40-5277121C8362Q34551903-DCA16551-28A4-4349-AD31-20679D1EC51DQ34699410-5AA40746-E70B-4B14-8E5C-AA029BB765E8Q34702388-D0B64D82-9EB9-4AD8-9D77-41EA36EF52E9Q34765364-759DAFA8-61E2-4A79-B105-74EDB324A912Q34829230-A54EA438-EE75-43FC-B38B-706C97F17EFEQ35077659-7E1C2CEB-B8BA-4FBD-A595-6D59176D77A4Q35110635-A0AEC8B8-0BF0-45BA-856D-9D96782589EEQ35532093-71A0082E-2B1C-453B-BD50-2F1D3186AF49Q35642841-BFA28EBC-B9E6-4456-A24C-4B3A995FC7B4Q35694476-8BD3058F-4DE6-43E8-A109-E33EEEA60417Q35855949-088A1A5E-1C51-4D2F-ACE4-3FFE73E31A8DQ36348471-BD91D6AF-C874-4389-97D0-0ED197643882Q36742259-8580C4AC-82EC-4B6B-80C2-F75463C0B427Q37363593-85A4731C-D23A-4BC0-8A9F-D271A3868E92Q37373970-1CDC416E-3516-4450-A45F-2F2198F1B613Q37408968-CB90BD94-4BE9-4354-8A57-B46EA4AC3523Q37624281-C7284C70-3A48-41BA-99EE-71342ABC0F5FQ37876825-DA1AD300-5BA7-4CA6-81FF-A3D403B8ACE9Q37879581-BE1D04C0-3F8B-428E-98EB-6973FBD07257Q37955304-2C782859-9EDC-4266-A9CC-010007CA7C98Q37958731-55E93A18-2028-4086-A8FE-31FA008EFDB5Q38169237-E3F944F2-7AFD-4F86-83B7-AE45972D6C91Q38241348-43F1BBA1-5335-4758-984D-DB9E09553C7EQ38264533-93376E29-A250-4802-8A3E-78739436BA28Q38445000-F4F4F677-D25D-47AE-A694-0FAF3FE627FEQ38757723-B45E9F21-E38D-46E8-A3A2-B3D96802F3A9Q38803373-54136510-0D2D-4255-99EC-81E131FF6D5BQ38910151-D467DB9B-18B3-49DE-9A04-FE6493F6DCDFQ38979348-B7AAFCFF-A635-492F-8689-645A942EC9C0
P2860
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Microtubule depolymerizing vas ...... ncology and other pathologies.
@en
Microtubule depolymerizing vas ...... ncology and other pathologies.
@nl
type
label
Microtubule depolymerizing vas ...... ncology and other pathologies.
@en
Microtubule depolymerizing vas ...... ncology and other pathologies.
@nl
prefLabel
Microtubule depolymerizing vas ...... ncology and other pathologies.
@en
Microtubule depolymerizing vas ...... ncology and other pathologies.
@nl
P2860
P1476
Microtubule depolymerizing vas ...... ncology and other pathologies.
@en
P2093
Chryso Kanthou
Gillian M Tozer
P2860
P304
P356
10.1111/J.1365-2613.2009.00651.X
P577
2009-06-01T00:00:00Z